2325 GMT - Cochlear shakes off its bear at UBS thanks to the 14% share-price dive that followed the hearing-implant maker's 1H result. Analyst Laura Sutcliffe raises her recommendation on the Australia-listed stock to neutral from sell, telling clients in a note that the result wasn't as bad as it looked. She isn't totally convinced by the company's expectation of 10% implant unit growth in the June half, calling it a big ask. However, she sees Cochlear's confidence in such a growth rate going forward as important. UBS lifts its target price 5.6% to A$285.00. Shares are up 2.6% at A$269.64. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 16, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。